DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
BMY-14802 is an investigational drug.
There have been 8 clinical trials for BMY-14802. The most recent clinical trial was a Phase 2 trial.
The most common disease conditions in clinical trials are HIV Infections, AIDS-Related Complex, and Infection. The leading clinical trial sponsors are Bristol-Myers Squibb, National Institute of Allergy and Infectious Diseases (NIAID), and Northwestern University.
Recent Clinical Trials for BMY-14802
|Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer||National Cancer Institute (NCI)||Phase 2|
|Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer||Northwestern University||Phase 2|
|A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment||Bristol-Myers Squibb||Phase 2|